Valeant Pharmaceuticals International Inc (NYSE:VRX)(TSX:VRX) stated on Thursday that it plans to pay down another USD200m of its senior secured term loans with cash on hand.

Following the repayment of debt next week, the company will have reduced its debt, in aggregate, by more than USD6.7bn since the end of Q1 2016.

In conjunction, the company's total long-term debt will be about USD25.5bn.

The specialist pharmaceutical company develops, manufactures and markets a broad range of pharmaceutical products in dermatology, gastrointestinal disorders, eye health, neurology and branded generics.